PGEN · XBRL financial data

Precigen financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	—	year only	—	—	—	year only	1	1	—	year only	23	55
Research and development	—	year only	—	—	—	year only	10	11	—	year only	6	7
Selling, general and administrative	—	year only	—	—	—	year only	12	16	—	year only	21	22
Total operating expenses	—	year only	—	—	—	year only	24	33	—	year only	29	32
Operating income (loss)	—	year only	—	—	—	year only	(23)	(32)	—	year only	(6)	23
Interest expense	—	year only	—	—	—	year only	0	0	—	year only	3	3
Other income (expense)	—	year only	—	—	—	year only	0	(0)	—	year only	0	0
Income tax expense (benefit)	(0)	(0)*	(0)	(2)	0	(0)*	0	0	0	0*	0	0
Net income (loss)	(20)	(33)*	(24)	(59)	(24)	(20)*	(54)	(27)	(146)	(24)*	(8)	20
Earnings per share, basic USD per share	(0.08)	(0.13)*	(0.10)	(0.23)	(0.09)	(0.07)*	(0.18)	(0.09)	(1.06)	(0.07)*	(0.02)	0.06
Earnings per share, diluted USD per share	(0.08)	(0.13)*	(0.10)	(0.23)	(0.09)	(0.07)*	(0.18)	(0.09)	(1.06)	(0.07)*	(0.02)	0.05
Weighted average shares, basic millions of shares	249	252*	249	252	276	293*	294	296	307	354*	354	357
Weighted average shares, diluted millions of shares	249	252*	249	252	276	293*	294	296	307	354*	354	414

Fiscal quarters (PGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	10	8	17	9	25	30	6	14	14	30	7	16
Short-term investments	64	55	27	10	4	68	74	46	107	68	49	22
Marketable securities, non-current	5	—	—	—	—	0	1	—	3	3	0	0
Accounts receivable	1	1	1	1	0	1	1	0	1	4	26	72
Prepaid and other current assets	5	4	4	3	5	3	3	2	4	3	4	4
Total current assets	93	69	50	24	35	102	85	63	130	115	102	134
Property and equipment, net	7	7	13	13	14	14	15	15	15	14	13	13
Right-of-use asset	7	7	7	6	5	5	5	5	5	5	4	4
Goodwill	37	27	27	25	25	19	19	15	15	15	15	15
Total assets	191	151	135	73	83	145	129	102	171	156	139	170
Accounts payable	2	2	5	5	4	4	3	4	6	12	3	5
Total current liabilities	33	23	29	23	21	22	24	23	32	37	21	29
Long-term debt	—	—	—	—	—	0	—	—	—	93	94	94
Lease liability, non-current	6	6	5	5	5	5	4	4	4	4	4	3
Total liabilities	43	33	38	30	28	79	113	108	129	135	118	127
Accumulated deficit	(1,931)	(1,964)	(1,988)	(2,047)	(2,071)	(2,091)	(2,145)	(2,172)	(2,318)	(2,341)	(2,349)	(2,329)
Total stockholders' equity	148	118	97	43	55	39	(14)	(37)	42	21	20	44
Total liabilities and equity	191	151	135	73	83	145	129	102	171	156	139	170
Common shares outstanding (cover page) millions of shares	249	249	252	253	293	294	295	298	354	354	357	358

Fiscal quarters (PGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(20)	(33)*	(24)	(59)	(24)	(20)*	(54)	(27)	(146)	(24)*	(8)	20
Stock-based compensation	2*	2*	3	2*	2*	3*	3	2*	4*	2*	3	4*
Depreciation and amortization	2*	2*	2	2*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(17)*	(16)*	(14)	(23)*	(23)*	(8)*	(16)	(19)*	(29)*	(23)*	(44)	(18)*
Purchases of property and equipment	0*	1*	4	2*	1*	1*	1	1*	0*	0*	0	0*
Net cash from investing activities	11*	13*	24	15*	6*	(65)*	(6)	28*	(63)*	40*	21	27*
Proceeds from issuing common stock	0*	0*	0	0*	32*	(1)*	(0)	0*	0*	0*	0	0*
Proceeds from long-term debt	—	year only	—	—	—	0*	—	—	—	(1)*	—	—
Repayments of long-term debt	0*	0*	0	0*	0*	0*	—	—	—	year only	—	—
Net cash from financing activities	0*	0*	0	0*	32*	78*	(1)	(2)*	93*	(1)*	0	(0)*
Net change in cash	(7)*	(2)*	10	(8)*	15*	5*	(23)	8*	1*	16*	(23)	9*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Precigen	16	55	(18)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17	not reported	(2.2)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48	not reported	(21)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	225	0	(40)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	83	117	0.8*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	16	not reported	(9.2)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.